PNH

Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting

Initial Physician Experience with Eculizumab in Patients with Other Rare Complement-Mediated Diseases also to be Presented CHESHIRE, Conn., Nov. 10 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that the American Society of Hematology (ASH) has publi...

Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a treatment for patients with PNH, will be presented at the 2007 American Soc...

Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute

... About Soliris Soliris is the first product approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the U.S. and Europe. pnh is a rare, debilitating, and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemoly...

Connecticut Bioscience Achievement Awards Presented at CURE Annual Meeting

...t biotechnology company to have a product approved for marketing. Earlier this year Alexion launched Soliris(R), a pharmaceutical for the treatment of pnh (paroxysmal nocturnal hemoglobinuria), a rare blood disorder. Dr. Leonard Bell is CEO and David Keiser is president and COO of Alexion. The Atlas Aw...

Nerve Disorganization May Spur Form of Dyslexia

...(PNH), which disrupts brain structure. People with pnh have normal intelligence but have trouble reading ...d for this aspect of reading. They compared the pnh patients to 10 people with dyslexia without neurol...atter nerve fiber connections in the brains of the pnh patients. The more disordered a patient's white ma...

FDA Approves First-of-its-Kind Drug to Treat Rare Blood Disorder

...g upon the severity of the disorder, patients with pnh may have pain, fatigue and debilitating weakness, ...ment system activity, including the destruction of pnh red blood cells. FDA based its approval on ...cebo-controlled clinical study of 87 patients with pnh and a series of other clinical studies. The contro...

PNH in Medical Technology

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

Data Suggest Role of Hemolysis in PNH-Related Fatigue Presentation at the European Hematology Association 13th Congress CHESHIRE, Conn., June 15 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab) therapy improved the often disabling fatigue experienced by patients with the rare blood...

Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

CHESHIRE, Conn., March 20 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (the "Company") (Nasdaq: ALXN ) today announced that it has completed enrolling patients in its previously announced AEGIS study, a single registration study to evaluate the safety, efficacy, and pharmacology of...

Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

CHESHIRE, Conn., Jan. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (the "Company," Nasdaq: ALXN) today announced that it has commenced dosing in the AEGIS study, a single registration study to evaluate the safety, efficacy, and pharmacology of Soliris(R) (eculizumab) as a treatmen...

PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity

Data Presented at the American Society of Hematology (ASH) Annual Meeting Publication Number: 840 CHESHIRE, Conn., Dec. 11 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab) therapy reduced hemolysis, fatigue, thromboses (blood clots) and transfusion requirements in patien...

Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients

Results of SHEPHERD Phase III Open Label Trial Published in Online Edition of the Journal Blood CHESHIRE, Conn., Dec. 4 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab) therapy reduced hemolysis and improved fatigue, overall quality of life and anemia in a diverse popu...

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-sp...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

Study Shows that Long-Term Soliris Therapy Continued to Be Associated with Reductions in Thrombosis and Improvements in Fatigue, Quality of Life, and Anemia in PNH Patients Data Presented at the American Society of Hematology (ASH) Annual Meeting Po...

Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes

- Analysis of Phase III Data Presented at ASCO - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Investigators reported today that Soliris(TM) (eculizumab), a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) developed by Alexion Pharmaceuticals, Inc. , is effective in patients diagnose...

Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients

- Data presented at 12th Congress of European Hematology - CHESHIRE, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced results from three analyses of Phase III studies examining Soliris(TM) (eculizumab) for the treatment of paroxysmal nocturnal hemoglobin...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

...h PNH. Soliris is the first therapy approved in Europe for the treatment of pnh and was the first medicinal product to receive EC approval under the EMEA A...tibiotics if necessary." During clinical studies, two out of 196 vaccinated pnh patients treated with Soliris experienced a serious meningococcal infection...

PNH in Biological Technology

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

CHESHIRE, Conn., Dec. 9 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ), was observed by investigators to reduce blood measures associated with undiagnosed blood clots and inflammation in patients with ...

Alexion Reports Third Quarter 2008 Results

... "The Award reflects our ongoing commitment to the pnh community, and also points to the potential of our...ith the FDA approval of Soliris as a treatment for pnh in 2007, Alexion became the first company to disco...PNH, resulting in more effective identification of pnh patients. In Europe, more patients in more countri...

Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product

...mponent of the normal immune system. Patients with pnh lack naturally occurring proteins that ordinarily ...e committed to making sure that every patient with pnh who can benefit from Soliris will have access to S...cess of Soliris by increasing our understanding of pnh and by evaluating the promise of complement inhibi...

Alexion Reports First Quarter 2008 Results

... Growing Awareness of pnh Drives Strong Demand for Soliris(R) in U.S. and ...akes it possible for us to help more patients with pnh and research promising therapies for other serious...opment: Soliris as a Treatment for Patients with pnh -------------------------------------------- A...

Alexion Reports Fourth Quarter and Full Year 2007 Results

...of urgency in detecting and treating patients with pnh as early as possible," said Leonard Bell, M.D., Ch...ontinue to execute our launch plan by facilitating pnh patient access to Soliris, while also assisting ph...ysicians, through education, to diagnose and treat pnh with greater effectiveness," said David Keiser, Pr...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

...all/ -- Patients with a rare blood disorder called pnh experienced a 92 percent reduction in the incidenc...ombosis is the leading cause of premature death in pnh patients and the most feared complication of PNH,"... clinical trials, Soliris reduced hemolysis in all pnh patients and significantly improved anemia, fatigu...